Explore our high-purity Active Pharmaceutical Ingredients, customized peptide formulations, and therapeutic raw materials produced under stringent cGMP standards.
Driving innovation across global pharmaceutical supply chains with state-of-the-art infrastructure and rigorous quality compliance.
An authoritative technical evaluation of active pharmaceutical ingredients, neuro-vascular protective compounds, and scalable Chinese chemical manufacturing pipelines.
The global healthcare paradigm is undergoing a massive shift toward targeted molecular therapies addressing Cardio-Cerebral Vascular System diseases. Cardiovascular diseases (CVDs) and cerebrovascular disorders—including ischemic stroke, myocardial infarction, coronary artery disease, and metabolic-induced endothelial dysfunction—remain the leading causes of global mortality. Consequently, multinational pharmaceutical companies, biotechnology enterprises, and clinical research institutions face mounting pressure to secure reliable, highly compliant, and cost-effective suppliers for Active Pharmaceutical Ingredients (APIs), key intermediates, and custom therapeutic peptides.
Modern drug discovery for cardio-cerebral therapeutics extends far beyond traditional antihypertensive or antiplatelet agents. Current clinical pipelines heavily leverage metabolic regulation, mitochondrial stabilization, and microvascular endothelial repair. Small molecules and peptide APIs act directly on specialized physiological receptors to prevent cellular ischemia and re-establish vascular homeostasis:
To support global research organizations and commercial formulation developers, Gentolex Group delivers a comprehensive catalog of high-purity APIs, peptide raw materials, and fine chemical precursors. The table below details critical compounds within our cardio-cerebral and metabolic supply portfolio:
| Compound / Active Ingredient | CAS Number / Sequence | Primary Clinical Application | Purity & Standards |
|---|---|---|---|
| Liraglutide API | CAS 204656-20-2 | GLP-1 Receptor Agonist; Cardiovascular Risk Reduction & Glycemic Regulation | ≥98.0% (HPLC); cGMP Grade |
| Semaglutide API | CAS 910463-68-2 | T2DM Treatment, Obesity Management, Atherosclerosis Attenuation | ≥99.0% (HPLC); Lyophilized Powder |
| SS-31 (Elamipretide) | MTP-131 / Bendavia | Mitochondrial Target; Myocardial Ischemia & Cerebrovascular Protection | ≥98.5% (HPLC); Custom Synthesis |
| BPC-157 Pentadecapeptide | CAS 137525-51-0 | Vascular Endothelial Repair, Angiogenesis Acceleration, Organ Protection | ≥99.0% (HPLC); Mass Spec Validated |
| Selank Acetate API | TKPRPGP Sequence | Neuroprotective, Anxiolytic, Ischemic Brain Injury Recovery Support | ≥98.0% (HPLC); cGMP Documented |
| Dihexa Compound | PNB-0408 | Synaptogenic Neuroactive Agent, Cognitive & Cerebral Vascular Functional Support | ≥99.0% (HPLC & NMR); Industrial Fine Chemical |
Global pharmaceutical sourcing directors increasingly lean on China for chemical sourcing due to unparalleled backward integration, high-capacity solid-phase peptide synthesis (SPPS), and robust regulatory progression. As a leading manufacturer and supply chain integrator, Gentolex Group operates a state-of-the-art production complex spanning over 250,000 square meters.
Our key supply chain advantages include:
Direct access to basic raw material manufacturers and specialized building blocks (e.g., protected amino acids like Fmoc-Ile-αMeLeu-Leu-OH) drastically reduces raw material lead times and insulates client operations from international price volatility.
Every commercial batch undergoes exhaustive testing including High-Performance Liquid Chromatography (HPLC), Mass Spectrometry (LC-MS), Nuclear Magnetic Resonance (NMR), and Karl Fischer moisture titration to guarantee absolute structural fidelity and ultra-low endotoxin levels.
Our large-scale manufacturing infrastructure lowers unit costs for advanced synthetic peptides and small molecules, allowing global pharmaceutical developers to optimize R&D budgets while preserving clinical-grade quality.
Navigating global healthcare markets requires strict adherence to international regulatory frameworks. Gentolex Group bridges the gap between raw chemical synthesis and commercial drug launch by offering comprehensive technical dossiers (DMF), Certificate of Analysis (CoA), and finished dosage form (FDF) licensing out capabilities.
We provide localized technical assistance and regulatory consulting tailored to key expanding markets across North America, Europe, Latin America, and Africa. With physical sales representatives and strategic distribution centers established in Mexico and South Africa, we guarantee seamless customs clearing, cold-chain handling, and localized technical dialogue.
End-to-end solutions spanning raw peptide APIs, custom contract development, turn-key laboratory setup, and global supply management.
Our main services focus on supplying peptides APIs and Custom Peptides, FDF license out, Technical Support & Consultation, Product Line and Lab Setup, Sourcing & Supply Chain Solutions.
An overall factory construction area of 250,000 square meters under international standard to offer flexible, scalable and cost-effective solutions.
Gentolex offers an extensive range of APIs and intermediates for development study and commercial application with cGMP standard from long-term collaborations. Documents and Certificates are supported to customers worldwide.
Specialized R&D infrastructure capable of high-throughput peptide synthesis, custom modifications, peptide mapping, and stable isotope labeling for clinical trials.
For those clients who prefer to avoid the complexity of dealing with multiple points of contact, we provide extra customized procurement services with the most superior and comprehensive supply chain sources.
Gentolex’s goal is to create opportunities connecting the world with better services and guaranteed products. Up to date, Gentolex Group has been serving customers from more than 10 countries, specially, representatives are established in Mexico and South Africa. Our main services focus on supplying peptides APIs and Custom Peptides, FDF license out, Technical Support & Consultation, Product Line and Lab Setup, Sourcing & Supply Chain Solutions.
Latest updates on neuroactive peptides, active pharmaceutical ingredients, global logistics, and biochemical research.
Selank Acetate API is a synthetic heptapeptide active pharmaceutical ingredient (API) composed of the amino acid sequence Thr-Lys-Pro-Arg-Pro-Gly-Pro (TKPRPGP). Originally developed through neuropharmacological research, Selank is a derivative of the endogenous...
As a professional Thymosin Beta-4 API manufacturer and supplier, we provide high-quality Thymosin Beta-4 peptide API solutions for biotechnology companies, pharmaceutical research organizations, and life science entities globally...
BPC-157 API is a synthetic pentadecapeptide that has gained increasing attention in peptide research due to its potential biological activities related to tissue repair, gastrointestinal protection, angiogenesis, and inflammatory regulation...
With the continuous development of neuroscience, peptide technology, and life science research, neuroactive peptides have become an important area of scientific investigation. Semax, a synthetic peptide derived from an ACTH fragment, has attracted attention...
SS-31 API, also known as Elamipretide, MTP-131, Bendavia, and SS31, is a synthetic mitochondria-targeting tetrapeptide designed to bind cardiolipin in the inner mitochondrial membrane. By stabilizing mitochondrial structure and supporting cellular bioenergetics...
Direct answers for global purchasing managers, regulatory specialists, and drug formulation engineers.
Explore the remainder of our fine chemical, synthetic peptide, and pharmaceutical intermediate portfolio.
